Tessera Therapeutics is developing a new class of gene editors capable of precisely plugging in long stretches of DNA—something that Crispr can’t do.
We’ll need millions of vials to distribute the vaccine. The US government thinks manufacturing methods from the semiconductor industry can help.
After George Floyd’s killing, experts warned that demonstrations could set off new waves of infections. But early testing in Minneapolis tells another story.
Anti-vaccine messages on social media have tripled since the pandemic began. One public health group wants to teach pro-vaccine Americans to fight fire with fire.
On June 10, thousands of academics are stopping research activities to educate themselves about disparities and take action against systemic racism in science.
The easing of stay-at-home orders and Memorial Day travel have led to spikes in some parts of the country. That’s bad news for what comes next.
Worried about infiltration from extremist groups or police surveillance, residents are turning to pre-internet tactics to help protect homes and local stores.
Since January, scientists have published more than 700 studies to figure out the molecule’s link to risk for the disease—and to find possible treatments.
With lockdowns ending, people have a lot of questions about how to calculate the risks of returning to everyday activities. Erin Bromage has answers.
The coronavirus has hit meat processing plants hard. But not in Denmark, where automation makes for safer slaughterhouses.